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formation on the impact of different ART regimens on inﬂammatory
biomarkers linked with mortality remains, however, very limited. Re-
cently, integrase inhibitors have shown to improve inﬂammation or im-
mune activation markers when compared to non-nucleoside reverse
transcriptase inhibitors. In particular, when compared to efavirenz,
raltegravir normalized the CD4/CD8 ratio faster than efavirenzAntiretroviral therapy (ART) is among the greatest successes of
modernmedicine. The vastmajority of patients taking ARTwill success-
fully control HIV replication,with the subsequent immunological recov-
ery and an uneventful clinical course in most patients. Moreover, safety
of the new drugs currently in use has been improved so that discontin-
uations due to adverse events have beenminimized. Many studies sug-
gest now that the lifespan of HIV-infected persons on ART might equal
that of the non-HIV infected population. Only an excess morbidity and
mortality associated to the development of the so-called non-AIDS
events remains as a signiﬁcant clinical problem (Rasmussen et al.,
2015; Marcus et al., 2016).
It has been well demonstrated that non-AIDS events, including car-
diovascular disease, non-AIDS cancers, osteoporosis, liver failure, renal
failure, neurocognitive impairment, and frailty, as well as overall-mor-
tality in HIV-infected patients on otherwise successful ART are related
with persistent inﬂammation and immune activation (Kuller et al.,
2008; Borges et al., 2013; Hunt et al., 2016). The ultimate cause of this
residual inﬂammation is not well understood, but persistent HIV-repli-
cation, bacterial translocation, aging, lifestyle factors, and coinfections,
among others, have been advocated as contributors (High et al., 2012).
Since the relationship between inﬂammation and non-AIDS morbidity
and mortality was established, there have been multiple attempts to
ﬁnd strategies that could help improve the situation. As the direct im-
pact of any strategy on clinical endpoints requires large numbers of pa-
tients and long follow-up, most clinical trials and studies have evaluated
the impact on markers of inﬂammation/immune activation previously
shown to be associated with clinical outcomes. Early initiation of ART
has been associated with a signiﬁcant decrease in the number of non-
AIDS events in a large clinical trial (Lundgren et al., 2015), but no
other studies with different strategies have offered similar results.
Antiretroviral drugs have also been a focus of attention for this pur-
pose. A differential impact of drug families and individual drugs hasom.2016.10.009.
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,been the hypothesis for some analysis of randomized clinical trials. In-
(Serrano-Villar et al., 2016), and elvitegravir/cobicistat induced larger
decreases of markers of monocyte activation (sCD14), systemic
(hsCRP) and vascular inﬂammation (Lp-PLA2) (Hileman et al., 2015)
No such analysis has been performed so far with the nucleos(t)ide re-
verse transcriptase inhibitors (NRTIs) which are included in all the rec-
ommended regimens for treatment initiation of HIV-infection.
For this reason, the article by Funderburg et al. in this issue of
EBioMedicine (Funderburg et al., 2016) is especially pertinent. Based
on a large, double-blind clinical trial, this substudy examines changes
in different biomarkers of local and systemic inﬂammation, comparing
tenofovir alafenamide (TAF) with tenofovir disoproxil fumarate (TDF)
both in combination with emtricitabine and elvitegravir/cobicistat
TAF is a new prodrug of tenofovir diphosphate that has been shown to
have an efﬁcacy similar to TDF while improving the renal and bone tox-
icity in clinical trials. However, information on the changes in markers
of inﬂammation is lacking. The results show that, as expected, there
were signiﬁcant declines of most markers from baseline in both arms
and that TAF is as effective as TDF at reducing markers of immune acti-
vation and inﬂammation associated with the development of non-AIDS
events and all-cause mortality.
In addition to being the ﬁrst report on the impact of different NRTIs
in the changes in inﬂammation biomarkers, the information provided in
this article is relevant for several reasons. Tenofovir-based regimens are
thepreferred choice formost patients throughout theworld, so any new
information on the drug will have an impact on a large number of per-
sons. In the near future,manypatientswill begin therapywith orwill be
switched to a TAF-based regimen, based on the good efﬁcacy and safety
proﬁle of the drug compared to TDF. So, providing information
supporting a beneﬁcial anti-inﬂammatory proﬁle is reassuring for
both physicians and patients. Even if we have learnt that TAF does not
outperform TDF at this regard, we can inform our patients now about
the lack of any potential loss of previous beneﬁt with TAF-based regi-
mens, at least in the short term.
We have reached nearly optimal levels in individual antiretrovira
drugs and in combination therapies. The goal of achieving durable sup-
pression of HIV replication and long-standing undetectable viral load
with a well-tolerated, non-toxic regimen is now an accessible task for
32 S. Moreno, S. Serrano-Villar / EBioMedicine 13 (2016) 31–32most physicians in the world. But persistent immune activation and in-
ﬂammation despite virological control still persists, as do the associated
clinical events that determine the long-termmorbidity andmortality of
treated patients. Information on the effect of antiretroviral drugs and
regimens on these important effects are needed. Practicing physicians
will certainly welcome it.
Disclosure
The authors declare no competing interests.
References
Borges, A.H., Silverberg, M.J., Wentworth, D., et al., 2013. Predicting risk of cancer during
HIV infection: the role of inﬂammatory and coagulation biomarkers. AIDS 27,
1433–1441.
Funderburg, N.T., McComsey, G.A., Kulkarnia, M., et al., 2016. Equivalent decline in inﬂam-
mation markers with tenofovir disoproxil fumarate vs. tenofovir alafenamide.
EBioMedicine 13, 321–327.High, K.P., Brennan-Ing, M., Clifford, D.B., et al., 2012. HIV and aging: state of knowledge
and areas of critical need for research. A report to the NIH Ofﬁce of AIDS research
by the HIV and aging working group. J. Acquir. Immune Deﬁc. Syndr. 60 (Suppl 1),
S1–18.
Hileman, C.O., Kinley, B., Scharen-Guivel, V., et al., 2015. Differential reduction in mono-
cyte activation and vascular inﬂammation with integrase inhibitor-based initial anti-
retroviral therapy among HIV-infected individuals. J. Infect. Dis. 212, 345–354.
Hunt, P.W., Lee, S.A., Siedner, M.J., 2016. Immunologic biomarkers, morbidity, andmortal-
ity in treated HIV infection. J. Infect. Dis. 214 (Suppl 2), S44–S50.
Kuller, L.H., Tracy, R., Belloso, W., et al., 2008. Inﬂammatory and coagulation biomarkers
and mortality in patients with HIV infection. PLoS Med. 5, e203.
Lundgren, J.D., Babiker, A.G., Gordin, F., et al., 2015. Initiation of antiretroviral therapy in
early asymptomatic HIV infection. N. Engl. J. Med. 373, 795–807.
Marcus, J.L., Chao, C.R., Leyden, W.A., et al., 2016. Narrowing the gap in life expectancy be-
tween HIV-infected and HIV-uninfected individuals with access to care. J. Acquir. Im-
mune Deﬁc. Syndr. 73, 39–46.
Rasmussen, L.D., May, M.T., Kronborg, G., et al., 2015. Time trends for risk of severe age-
related diseases in individuals with and without HIV infection in Denmark: a nation-
wide population-based cohort study. Lancet HIV e288–e298.
Serrano-Villar, S., Zhou, Y., Rodgers, A.J., Moreno, S., 2016. Different impact of raltegravir
versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients. J. Antimicrob.
Chemother. (in press).
